Background In patients with ischemic cardiomyopathy, mortality rate and quality of life are unsatisfactory. We investigated the effects of the metabolic agent trimetazidine (TMZ) on exercise tolerance and prognostic markers B-type natriuretic peptide (BNP) and cardiac troponin T (cTnT) plasma levels. Methods Fifty patients with ischemic cardiomyopathy were randomized either to receive TMZ (20 mg, TID) in addition to their conventional treatment (TMZ group, n = 25) or to continue their usual drug therapy (control group, n = 25) for 6 months. Patients were evaluated at baseline, at I month, and at 6 months (echocardiography and 6-minute walking test). At enrollment and at the end of follow-up, blood testing was performed for determination of BNP and cTnT plasma levels. Results After 6 months, no significant New York Heart Association class changes occurred in all patients (P = NS). In the TMZ group, a significant increase of exercise tolerance (P <.0 1) was detected, whereas left ventricular ejection fraction was unchanged (28% 4%, 29% 5%, and 32% 5% at baseline, at I month, and at 6 months, respectively; P = NS). In the TMZ group, BNP was significantly reduced (6 months, 135 22 vs 252 44 pg/mL; P <.001), whereas it was significantly increased in controls (6 months, 288 46 vs 239 59 pg/mL; P <.02); cTnT significantly (P <.00 1) reduced during TMZ treatment, whereas it was unchanged in the control group. Conclusions Six-month TMZ treatment improves exercise tolerance and reduces plasma levels of BNP and cTnT in patients with compensated ischemic cardiomyopathy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据